 FDA’s Office of Generic Drugs works to better understand public perceptions of generic drugs
Generic medications are safe and effective, just as their brand-name counterparts, and often cost less, providing consumers and the healthcare system significant savings. Lack of awareness about generic medications and the stringent FDA application review process may lead patients to continue to use brand-name medications, even when more affordable generics are available. These misconceptions may also cause patients who are “switched” to a generic drug not to take their generic treatment. Both instances may lead to a decrease in medication adherence and, ultimately, worse health outcomes.
Please read this CDER Conversation where Iilun Murphy, MD, Director of CDER's Office of Generic Drugs (OGD), discusses how OGD is conducting and funding research to better understand how the office can best educate patients and health care providers about generic drugs.
|
